Phase 3 clinical trial of ambroxol for Parkinson's confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Learn more
2026: reflecting on the last year’s research progress and looking at what’s ahead
2025 was one of our most exciting years yet for Parkinson’s research. We saw the launch of EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, the start of recruitment for the phase 3 trial of ambroxol, the forging of new strategic partnerships, and much…
New registry Join Parkinson’s Research aims to boost awareness and accessibility of clinical research studies for Parkinson’s
The Join Parkinson’s Research (JPR) registry is a new online platform where people living with the condition can register to hear about the latest clinical studies. Clinical research studies are vital to improve our understanding of Parkinson’s and help develop new treatments. However, due to…
SLEIPNIR, the new multi-arm clinical trial platform for Parkinson’s treatments
Cure Parkinson’s is excited to announce £1 million in funding for SLEIPNIR – an upcoming multi-arm clinical trial platform in Norway. One of the ongoing challenges for Parkinson’s research is determining whether treatments are reaching the brain and if they are having their intended effect…
The AND-PD Trial
This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and followed for one year. This study, led by Professor Anette Schrag, is looking to recruit around…
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK. This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with Parkinson’s and…